V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 260009941 | 260006317 | 0 | 67.7 | null | 2018-06-02 | 2018-06-28 | BLEOMYCIN + VINCRISTINE | N | Y | 260012603 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |
| 260009942 | 260006317 | null | 0 | Curative (C) | 2017-08-17 | 2017-08-21 | Rituximab (SUBCUTANEOUS Maintenance) | N | N | 260012603 | CARBOPLATIN + PACLITAXEL |
| 260009943 | 260006318 | 1.89 | null | Adjuvant (A) | 2018-08-31 | 2018-09-07 | ABVD | 02 | Y | 260012647 | CARBOPLATIN + ETOPOSIDE |
| 260009944 | 260006318 | 1.69 | 77 | Palliative (P) | 2014-10-04 | 2014-10-12 | R Chlorambucil | N | N | 260012647 | CARBOPLATIN + ETOPOSIDE |
| 260009945 | 260006319 | null | 82 | Neo-adjuvant (N) | 2018-05-14 | 2018-05-18 | BOP | N | N | 260012670 | RITUXIMAB |
| 260009946 | 260006320 | 1.38 | 87.4 | Disease modification (D) | 2017-12-15 | 2018-01-03 | FEC 60 or 75 | 02 | N | 260012707 | BENDAMUSTINE |
| 260009947 | 260006321 | null | null | Not known (9) | 2018-03-06 | 2018-03-11 | ETOPOSIDE | Y | N | 260012719 | CISPLATIN + ETOPOSIDE |
| 260009948 | 260006321 | null | null | Curative (C) | 2017-06-24 | 2017-07-07 | Rituximab | N | N | 260012719 | RITUXIMAB |
| 260009949 | 260006321 | null | null | Palliative (P) | 2017-05-31 | 2017-06-01 | Bendamustine + prednisolone | 2 | N | 260012719 | RITUXIMAB |
| 260009950 | 260006321 | 1.69 | 0 | Adjuvant (A) | 2018-06-15 | 2018-06-15 | DHAP - R | N | N | 260012719 | TRIAL |
| 260009951 | 260006322 | 1.56 | null | Disease modification (D) | 2015-06-04 | 2015-06-04 | FCR Oral Lite | 2 | N | 260012747 | CAPECITABINE + OXALIPLATIN |
| 260009952 | 260006323 | 1.63 | 87.8 | Palliative (P) | 2014-11-30 | 2014-11-30 | Bendamustine +/- Prednisolone | 02 | Y | 260012760 | CHLORAMBUCIL + RITUXIMAB |
| 260009953 | 260006323 | 1.6 | 82 | null | 2014-09-10 | 2014-09-10 | Rituximab | 02 | N | 260012760 | CISPLATIN + VINORELBINE |
| 260009954 | 260006323 | 1.88 | 90 | null | 2017-06-18 | 2017-06-22 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 02 | null | 260012760 | CISPLATIN + ETOPOSIDE |
| 260009955 | 260006323 | null | null | Curative (C) | 2018-04-01 | 2018-04-02 | Carboplatin + Pemetrexed | 2 | N | 260012760 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260009956 | 260006324 | 1.65 | 0 | Adjuvant (A) | 2013-05-20 | 2013-05-28 | Rituximab | N | N | 260012924 | SUNITINIB |
| 260009957 | 260006325 | 1.69 | 68.3 | null | 2017-08-25 | 2017-09-02 | BLEOMYCIN + CISPLATIN + ETOPOSIDE + PACLITAXEL | 2 | null | 260012930 | RITUXIMAB |
| 260009958 | 260006325 | 1.6 | null | Curative (C) | 2016-01-01 | 2016-01-01 | CHOP - 21 days | 02 | N | 260012930 | FEC |
| 260009959 | 260015716 | 1.79 | 93.5 | Curative (C) | 2018-09-01 | 2018-09-03 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 2 | N | 260013003 | EP |
| 260009960 | 260006326 | 1.76 | null | null | 2018-09-16 | 2018-09-23 | Trial Unspecified | 02 | N | 260013004 | CISPLATIN + ETOPOSIDE |
| 260009961 | 260006327 | 1.72 | 95.4 | Curative (C) | 2017-11-29 | 2017-12-05 | Cisplatin + Etoposide (3 day) | N | N | 260013059 | BLEOMYCIN |
| 260009962 | 260006327 | 1.73 | 89 | Curative (C) | 2019-04-16 | 2019-04-24 | BLEOMYCIN + CISPLATIN + VINCRISTINE | 2 | null | 260013059 | CISPLATIN + ETOPOSIDE |
| 260009963 | 260006327 | 1.62 | 78 | Adjuvant (A) | 2017-12-02 | 2017-12-16 | Carboplatin + Vinorelbine IV | N | N | 260013059 | SUNITINIB |
| 260009964 | 260006328 | 1.75 | 84.8 | null | 2016-10-15 | 2016-10-20 | BENDAMUSTINE | N | N | 260013127 | TRIAL |
| 260009965 | 260006328 | 1.64 | 70 | Disease modification (D) | 2015-03-16 | 2015-10-27 | Carboplatin 21day + Paclitaxel 7day | N | N | 260013127 | CISPLATIN + RT |
| 260009966 | 260006328 | 1.78 | 73.6 | Palliative (P) | 2016-12-27 | 2016-12-27 | CISPLATIN + ETOPOSIDE | 2 | N | 260013127 | CISPLATIN + ETOPOSIDE |
| 260009967 | 260006329 | 1.84 | 78.8 | Adjuvant (A) | 2017-11-29 | 2017-12-04 | Cisplatin + Etoposide (5 day) | N | N | 260013185 | EP |
| 260009968 | 260006329 | 1.84 | 74.6 | Palliative (P) | 2016-07-26 | 2016-08-23 | GC Int Guide Excranial GermCell JEB | N | N | 260013185 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |
| 260009969 | 260006329 | 1.66 | 72.3 | Adjuvant (A) | 2016-09-29 | 2016-10-14 | Rituximab | N | N | 260013185 | CISPLATIN |
| 260009970 | 260006330 | 1.6 | 63.5 | Disease modification (D) | null | 2014-05-28 | Rituximab | N | N | 260013280 | RITUXIMAB |
| 260009971 | 260006331 | 1.62 | 64.7 | Curative (C) | 2017-11-09 | 2017-11-12 | CARBOPLATIN + GEMCITABINE | N | N | 260013303 | RITUXIMAB |
| 260009972 | 260012435 | null | 119.6 | null | null | 2013-11-09 | GEMCARBO | N | null | 260013305 | IVA |
| 260009973 | 260006332 | 1.75 | 63.7 | Curative (C) | 2016-10-26 | 2016-11-25 | Cisplatin + Etoposide (5 day) | N | N | 260013375 | EP |
| 260009974 | 260006333 | 1.73 | null | Curative (C) | 2017-12-18 | 2017-12-21 | BLEOMYCIN + CISPLATIN + VINCRISTINE | 2 | N | 260013480 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260009975 | 260012436 | 1.55 | 87.5 | Palliative (P) | 2016-06-19 | 2016-06-21 | FEC 100 | N | N | 260013569 | TRIAL |
| 260009976 | 260012436 | null | null | Curative (C) | 2016-01-09 | 2016-01-09 | Cisplatin + Etoposide (5 day) | N | N | 260013569 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260009977 | 260006334 | null | 79 | Palliative (P) | 2018-02-26 | 2018-03-07 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | N | N | 260013665 | CISPLATIN + ETOPOSIDE |
| 260009978 | 260006335 | 1.78 | 84.6 | Disease modification (D) | 2018-09-27 | 2018-11-27 | Cisplatin + Etoposide (5 day) | N | N | 260013759 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + ETOPOSIDE + VINCRISTINE |
| 260009979 | 260006335 | 1.8 | 80.1 | null | 2017-12-26 | 2017-12-27 | IVADo | 02 | null | 260013759 | CISPLATIN + ETOPOSIDE |
| 260009980 | 260006336 | 1.62 | 84 | Palliative (P) | 2015-09-23 | 2015-09-28 | Rituximab | N | N | 260013870 | CARBOPLATIN + ETOPOSIDE |
| 260009981 | 260006336 | 1.7 | null | Disease modification (D) | 2017-03-11 | 2017-03-11 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 02 | N | 260013870 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260009982 | 260006336 | null | null | null | 2013-12-24 | 2013-12-24 | CVP | N | N | 260013870 | CISPLATIN + ETOPOSIDE |
| 260009983 | 260006337 | 1.67 | null | Curative (C) | 2017-01-08 | 2017-01-08 | BLEOMYCIN + VINCRISTINE | N | N | 260014155 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260009984 | 260006337 | 1.78 | null | Palliative (P) | 2015-04-30 | 2015-05-05 | EP | N | N | 260014155 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 260009985 | 260006338 | 1.59 | 60.8 | Curative (C) | 2019-03-16 | 2019-03-16 | Cisplatin + Radiotherapy | 01 | N | 260014327 | RITUXIMAB |
| 260009986 | 260006338 | null | 58.3 | null | 2017-12-23 | 2017-12-24 | Carboplatin + Etoposide iv&po | N | null | 260014327 | CISPLATIN + ETOPOSIDE |
| 260009987 | 260006338 | null | null | null | 2014-02-11 | 2014-02-11 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | null | 260014327 | CISPLATIN + ETOPOSIDE |
| 260009988 | 260006339 | 1.84 | 82 | Disease modification (D) | 2017-12-21 | 2017-12-24 | TIP | N | N | 260014427 | CISPLATIN + ETOPOSIDE |
| 260009989 | 260006339 | 1.6 | 63 | Curative (C) | 2015-11-13 | 2015-12-17 | CHOP - 21 days | N | N | 260014427 | BENDAMUSTINE |
| 260009990 | 260006340 | 1.85 | 55 | Curative (C) | null | 2015-12-30 | Carboplatin + Etoposide IV 3 day | null | null | 260014560 | VIP |